^(131)Ⅰ-抗AFP抗体导向治疗肝癌的临床观察  

CLINICAL STUDY OF ^(131)Ⅰ-LABELED ANTI-ALPHA FETOPROTEIN ANTIBODY FOR TARGETING THERAPY OF HEPATOCELLULAR CARCINOMA

作　　者：吴英德[1] 杨克政[1] 刘由庚[2] 周德南[2] 甘友全[2] 宋向群[1] 黄秉琰[1] 

机构地区：[1]广西医科大学附属肿瘤医院 [2]广西肿瘤防治研究所

出　　处：《肿瘤》1994年第4期200-203,共4页Tumor

摘　　要：１９８０～１９９３年，用（１３１）Ⅰ－抗ＡＦＰ抗体治疗不能切除肝癌７２例（１５３例次），治疗≥２次占４７例，平均（１３１）Ⅰ量为３１．８７（６．４～９７．４）Ｍｃｉ，中位数２７．４ｍｃｉ（１０１３．８ＭＢｑ）。结果：总有效率２０．８％（１５／７２），治后一年生存率３３．３％（２２／６６）；治疗≥２，≥３，≥４次者有效率分别为２９．８％（１４／４７）、６０．０％（９／１５）和７０．０％（７／１０）；一年生存率依次为４５．７％、７３．３％和８０．０％；瘤大小：≤７ｃｍ，７．１～１０ｃｍ和＞１０ｃｍ患者，治后瘤缩小率分别为１００．０％、７６．９％和５３．９％；一年生存率８７．５％、４８．０％和１５．４％；经肝动脉灌注治疗有效率高于ｉｖ给药者（６４．３％：１５．２％），一年生存率亦高于ｉｖ（６４．３％：３７．５％）。本研究表明，（１３１）Ⅰ－抗ＡＦＰ抗体导向治疗肝癌具有明显疗效。From 1980 to 1993, 72 cases with unresectable hepatocellular carcinoma were treated with polyclonal horse antibody against human AFP radiolabeled with 131Ⅰ.47 of the 72 cases were treated more than 2 times,the average dosage of 131Ⅰ is 31.8 mCi (range 6.4～97.4 mCi). The results showed:1,Overall response rate was 20.8%,1 year survival rate was 33.3%;2,After treated with 2,3 and≥4 times,the response rates were 29.7%,60.0% and 70.0%,and thd 1-year survival rates were 45.6%,70.3%and 80.0% respectively;3,47 cases with lesion size≤7cm,7.1～10cm,and>10cm in diameter,after treating the tumor shrinkage rate were 100%,76.9% ang 53.8% respectively;4,The response rate of the transarterial injection (TAI)was superior to the intravenous (iV) (64.3% v 15.2%) ,and the 1-year survival rate was 64.3% v 37.5%,This study indicated that 131Ⅰ-anti-AFP antibody is a much more effective treatment agent for HCC.

关 键 词：^(131)Ⅰ-抗AFP 导向治疗 肝癌 

分 类 号：R735.705[医药卫生—肿瘤]